These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 33886147)

  • 1. Antibody Glycoengineering and Homogeneous Antibody-Drug Conjugate Preparation.
    Manabe S; Yamaguchi Y
    Chem Rec; 2021 Nov; 21(11):3005-3014. PubMed ID: 33886147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homogeneous Antibody-Drug Conjugates via Glycoengineering.
    Tang F; Shi W; Huang W
    Methods Mol Biol; 2019; 2033():221-238. PubMed ID: 31332757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
    Yamada K; Ito Y
    Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current methods for the synthesis of homogeneous antibody-drug conjugates.
    Sochaj AM; Świderska KW; Otlewski J
    Biotechnol Adv; 2015 Nov; 33(6 Pt 1):775-84. PubMed ID: 25981886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
    Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
    Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Site-specific antibody drug conjugates for cancer therapy.
    Panowski S; Bhakta S; Raab H; Polakis P; Junutula JR
    MAbs; 2014; 6(1):34-45. PubMed ID: 24423619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site-Specific Quantitation of Drug Conjugations on Antibody-Drug Conjugates (ADCs) Using a Protease-Assisted Drug Deconjugation and Linker-like Labeling (PADDLL) Method.
    Yang X; Seol H; Lin W; Xu X; Shen B; Qiu H; Li N
    Anal Chem; 2021 Jul; 93(27):9549-9558. PubMed ID: 34196532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
    Tsuchikama K; An Z
    Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development.
    Li W; Zhu Z; Chen W; Feng Y; Dimitrov DS
    Front Immunol; 2017; 8():1554. PubMed ID: 29181010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A glyco-engineering approach for site-specific conjugation to Fab glycans.
    Jaramillo ML; Sulea T; Durocher Y; Acchione M; Schur MJ; Robotham A; Kelly JF; Goneau MF; Robert A; Cepero-Donates Y; Gilbert M
    MAbs; 2023; 15(1):2149057. PubMed ID: 36447399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
    Tsuchikama K
    Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
    Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D
    PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Properties of Cysteine-Conjugated Antibody-Drug Conjugates Are Impacted by the IgG Subclass.
    Datta-Mannan A; Choi H; Stokell D; Tang J; Murphy A; Wrobleski A; Feng Y
    AAPS J; 2018 Sep; 20(6):103. PubMed ID: 30255287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycans of Antibodies as a Specific Site for Drug Conjugation Using Glycosyltransferases.
    Qasba PK
    Bioconjug Chem; 2015 Nov; 26(11):2170-5. PubMed ID: 26065635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycoengineered antibodies: towards the next-generation of immunotherapeutics.
    Mastrangeli R; Palinsky W; Bierau H
    Glycobiology; 2019 Mar; 29(3):199-210. PubMed ID: 30289453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Protein Conjugation Strategies and Pioneering Anti-Cancer Applications.
    Mckertish CM; Kayser V
    Discov Med; 2023 Oct; 35(178):697-714. PubMed ID: 37811610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion.
    Dimasi N; Fleming R; Zhong H; Bezabeh B; Kinneer K; Christie RJ; Fazenbaker C; Wu H; Gao C
    Mol Pharm; 2017 May; 14(5):1501-1516. PubMed ID: 28245132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Site-specific antibody-drug conjugates with variable drug-to-antibody-ratios for AML therapy.
    Dai Z; Zhang XN; Cheng Q; Fei F; Hou T; Li J; Abdolvahabi A; Watanabe J; Pei H; Smbatyan G; Xie J; Lenz HJ; Louie SG; Zhang Y
    J Control Release; 2021 Aug; 336():433-442. PubMed ID: 34197861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of disulfide bond isoforms on drug conjugation sites in cysteine-linked IgG2 antibody-drug conjugates.
    Liu-Shin L; Fung A; Malhotra A; Ratnaswamy G
    MAbs; 2018; 10(4):583-595. PubMed ID: 29436897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing the choice of monoclonal antibodies for antibody-drug conjugates.
    Hasan MM; Laws M; Jin P; Rahman KM
    Drug Discov Today; 2022 Jan; 27(1):354-361. PubMed ID: 34597756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.